Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease

In conclusion, a lower serum level of HMW adiponectin was associated with a better response to dapagliflozin in patients with type 2 diabetes and NAFLD.
Trial registration number
UMIN000022155.

Source: Journal of Investigative Medicine - September 27, 2021 Category: Research Authors: Aso, Y., Sagara, M., Niitani, T., Kato, K., Iijima, T., Tomaru, T., Jojima, T., Usui, I. Tags: Original research Source Type: research